Scorr-Insert
X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lonodelestat

            Therapeutic Area: Pulmonary/Respiratory Diseases

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: CSHL

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration April 27, 2020

            Details:

            Santhera will provide lonodelestat and intellectual support for the scientists at CSHL who will conduct the non-clinical research program.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NI-0101

            Therapeutic Area: Pulmonary/Respiratory Diseases

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Edesa Biotech

            Deal Size: $372.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement April 20, 2020

            Details:

            The companies singed this exclusive worldwide license to develop and commercialize two Phase 2-ready biologic drug candidates for all therapeutic, prophylactic and diagnostic applications.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mesenchymal stem cells

            Therapeutic Area: Pulmonary/Respiratory Diseases

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Citius Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement April 01, 2020

            Details:

            Citius signed an exclusive six-month option agreement to in-license a stem-cell therapy for acute respiratory distress syndrome from a subsidiary of Novellus.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ifx-1

            Therapeutic Area: Pulmonary/Respiratory Diseases

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 31, 2020

            Details:

            InflaRx has dosed the first patient in an adaptive randomized controlled clinical study with IFX-1 in patients with severe COVID-19 pneumonia in the Netherlands.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mavrilimumab

            Therapeutic Area: Pulmonary/Respiratory Diseases

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 31, 2020

            Details:

            All 6 patients treated with mavrilimumab showed resolution of fever and did not progress to mechanical ventilation; follow-on controlled study in Italy planned.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sargramostim

            Therapeutic Area: Pulmonary/Respiratory Diseases

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 24, 2020

            Details:

            Leukine can be used for treating COVID-19 induced acute hypoxic respiratory failure and ARDS in a nebulized form for immediate inhalation or by intravenous injection.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ampion

            Therapeutic Area: Pulmonary/Respiratory Diseases

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 24, 2020

            Details:

            Ampio is preparing an expanded access FDA protocol to study potential benefit of nebulized treatment with Ampion in SARS-Cov-2 induced ADRS.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Gimsilumab

            Therapeutic Area: Pulmonary/Respiratory Diseases

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 18, 2020

            Details:

            Roivant will prioritize trials of gimsilumab in patients with COVID-19 instead of a Phase 2 trial in a separate disease area which had been previously planned.

            University of Pittsburgh

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Chemokine-derived antifibrotic peptides

            Therapeutic Area: Pulmonary/Respiratory Diseases

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: CSL Behring

            Deal Size: $0.2 million Upfront Cash: Undisclosed

            Deal Type: Partnership February 13, 2020

            Details:

            Universities awarded $250,000 research grants as part of the CSL Behring-Science Center Research Acceleration Initiative.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BXT-25

            Therapeutic Area: Pulmonary/Respiratory Diseases

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership February 05, 2020

            Details:

            Bioxytran seeks to explore collaborations with international drug makers to treat patients at the end stage of Acute Respiratory Distress Syndrome affected with Wuhan Coronavirus.